Lipid metabolism analysis in esophageal cancer and associated drug discoveryOA北大核心
Lipid metabolism analysis in esophageal cancer and associated drug discovery
Esophageal cancer is an upper gastrointestinal malignancy with a bleak prognosis.It is still being explored in depth due to its complex molecular mechanisms of occurrence and development.Lipids play a crucial role in cells by participating in energy supply,biofilm formation,and signal transduction pro-cesses,and lipid metabolic reprogramming also constitutes a significant characteristic of malignant tu-mors.More and more studies have found esophageal cancer has obvious lipid metabolism abnormalities throughout its beginning,progress,and treatment resistance.The inhibition of tumor growth and the enhancement of antitumor therapy efficacy can be achieved through the regulation of lipid metabolism.Therefore,we reviewed and analyzed the research results and latest findings for lipid metabolism and associated analysis techniques in esophageal cancer,and comprehensively proved the value of lipid metabolic reprogramming in the evolution and treatment resistance of esophageal cancer,as well as its significance in exploring potential therapeutic targets and biomarkers.
Ruidi Jiao;Wei Jiang;Kunpeng Xu;Qian Luo;Luhua Wang;Chao Zhao
Bionic Sensing and Intelligence Center,Institute of Biomedical and Health Engineering,Shenzhen Institute of Advanced Technology,Chinese Academy of Sciences,Shenzhen,Guangdong,518000,China||Department of Radiation Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital&Shenzhen Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Shenzhen,Guangdong,518116,China||School of Medicine,Southern University of Science and Technology,Shenzhen,Guangdong,518000,ChinaDepartment of Radiation Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital&Shenzhen Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Shenzhen,Guangdong,518116,ChinaBionic Sensing and Intelligence Center,Institute of Biomedical and Health Engineering,Shenzhen Institute of Advanced Technology,Chinese Academy of Sciences,Shenzhen,Guangdong,518000,China||University of Chinese Academy of Sciences,Beijing,100049,ChinaDepartment of Radiation Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital&Shenzhen Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Shenzhen,Guangdong,518116,China||School of Medicine,Southern University of Science and Technology,Shenzhen,Guangdong,518000,ChinaBionic Sensing and Intelligence Center,Institute of Biomedical and Health Engineering,Shenzhen Institute of Advanced Technology,Chinese Academy of Sciences,Shenzhen,Guangdong,518000,China||University of Chinese Academy of Sciences,Beijing,100049,China||Shenzhen Key Laboratory of Precision Diagnosis and Treatment of Depression,Shenzhen Institute of Advanced Technology,Chinese Academy of Sciences,Shenzhen,Guangdong,518000,China
Lipid metabolismEsophageal cancerProgressionTreatment resistanceNew therapeutic targets
《药物分析学报（英文）》 2024 (001)
1-15 / 15
The work was supported by the National Natural Science Foundation of China(Grant Nos.:22176195 and 82127801),Na-tional Key R&D Program of China(Grant No.:2022YFF0705003),the Shenzhen Key Laboratory of Precision Diagnosis and Treatment of Depression(Grant No.:ZDSYS20220606100606014),the Guangdong Province Zhu Jiang Talents Plan,China(Grant No.:2021QN02Y028),the Natural Science Foundation of Guangdong Province,China(Grant No.:2021A1515010171),the Key Program of Fundamental Research in Shenzhen,China(Grant No.:JCYJ20210324115811031),the Sustainable Development Program of Shenzhen,China(Grant No.:KCXFZ202002011008124),and the National Cancer Center/National Clinical Research Center for Can-cer/Cancer Hospital & Shenzhen Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Shenzhen(Grant Nos.:SZ2020ZD002 and SZ2020QN005).
评论